TSCAN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.8 USD | -2.62% |
|
-9.83% | +33.79% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 17.6M | Sales 2025 * | 15.66M | Capitalization | 446M |
|---|---|---|---|---|---|
| Net income 2024 * | -103M | Net income 2025 * | -119M | EV / Sales 2024 * | 21.4 x |
| Net cash position 2024 * | 68.9M | Net cash position 2025 * | 66.72M | EV / Sales 2025 * | 24.2 x |
| P/E ratio 2024 * |
-7.59
x | P/E ratio 2025 * |
-6.9
x | Employees | 154 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.78% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -2.62% | ||
| 1 week | -9.83% | ||
| Current month | +1.04% | ||
| 1 month | +4.70% | ||
| 3 months | +34.25% | ||
| 6 months | +80.97% | ||
| Current year | +33.79% |
1 week
7.34
8.95
1 month
6.589.09
Current year
4.649.09
1 year
1.939.09
3 years
1.4514.71
5 years
1.4514.71
10 years
1.4514.71
| Managers | Title | Age | Since |
|---|---|---|---|
Gavin MacBeath
CEO | Chief Executive Officer | 54 | 18-11-30 |
Jason Amello
DFI | Director of Finance/CFO | 55 | Jan. 28 |
Justin McCue
CTO | Chief Tech/Sci/R&D Officer | - | Dec. 03 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 76 | 19-02-28 | |
Stephen Biggar
BRD | Director/Board Member | 53 | 21-02-28 |
Gavin MacBeath
CEO | Chief Executive Officer | 54 | 18-11-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 7.8 | -2.62% | 238,819 |
| 24-05-08 | 8.01 | -7.61% | 111,214 |
| 24-05-07 | 8.67 | -1.59% | 107,057 |
| 24-05-06 | 8.81 | +2.92% | 97,441 |
| 24-05-03 | 8.56 | -1.04% | 88,682 |
Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm EDT
More quotes
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Companyâs lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company is advancing approximately six solid tumor programs: TSC-204, TSC-200, TSC-203, TSC-201, TSC-202 and TSC-205.
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.8
USD
Average target price
11.6
USD
Spread / Average Target
+48.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +33.79% | 446M | |
| +23.37% | 47.02B | |
| +49.51% | 41.86B | |
| -0.94% | 41.76B | |
| -5.86% | 28.8B | |
| +11.29% | 26.05B | |
| -20.92% | 19.15B | |
| +3.20% | 12.55B | |
| -2.67% | 11.82B | |
| +30.23% | 12.34B |
- Stock Market
- Equities
- TCRX Stock